untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:30:26Z</responseDate>
<request identifier=oai:HAL:hal-01134184v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01134184v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:IRSET-CCII</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:IRSET-1</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Interleukin 6 inhibits HBV entry through NTCP down regulation.</title>
<creator>Bouezzedine, Fidaa</creator>
<creator>Fardel, Olivier</creator>
<creator>Gripon, Philippe</creator>
<contributor>Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0042-6822</source>
<source>EISSN: 1096-0341</source>
<source>Virology</source>
<publisher>Elsevier</publisher>
<identifier>hal-01134184</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134184</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01134184</source>
<source>Virology, Elsevier, 2015, 481, pp.34-42. 〈10.1016/j.virol.2015.02.026〉</source>
<identifier>DOI : 10.1016/j.virol.2015.02.026</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.virol.2015.02.026</relation>
<identifier>PUBMED : 25765005</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/25765005</relation>
<language>en</language>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Hepatitis B virus (HBV) infection is a major public health problem. Recently, the human liver bile acid transporter Na+/taurocholate cotransporting polypeptide (NTCP) has been identified as an HBV specific receptor. NTCP expression is known to be strongly regulated by IL-6. This study was aimed at characterizing the effect of IL-6 on HBV entry. HBV entry was inhibited by up to 90% when cells were pretreated with IL-6 as shown by a strong inhibition of long term HBsAg secretion. This effect was confirmed by showing a severe reduction of intracellular HBV cccDNA. In parallel, we observed a 98% decrease in NTCP mRNA steady state level and an 80% reduction in NTCP-mediated taurocholate uptake. IL-6-mediated inhibition of NTCP-mediated taurocholate uptake and viral entry exhibited similar dose-dependence and kinetics while restoration of NTCP expression suppressed the inhibitory effect of IL-6. NTCP-mediated HBV entry is therefore markedly inhibited by IL-6.</description>
<date>2015-03-09</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
